Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.

Andrew Oar,Andrew Kneebone,Mark A. Lee,David Goldstein,Katrin Marie Sjoquist,Hien Le,Julie Chu,Andrew Barbour,Leily Gholamrezaei,James Lynam,Andrej Bece,Sandra Bahamad,Sonia Yip,David Espinoza,Lorraine A. Chantrill,Alisha Moore,Dominique Lee,Quoc Nam Nguyen,Jaswinder S. Samra,Jan Mumford

Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.

2021

TPS4172Background: Eighty per cent of patients with non-metastatic pancreatic cancer have high-risk, borderline resectable (BRPC) or locally advanced pancreas cancer (LAPC), conferring a 5-year ove...

Keywords:

FOLFIRINOX
Cancer
Medicine
stereotactic radiotherapy
Oncology
gastro intestinal
Internal medicine
Pancreatic cancer
locally advanced pancreatic cancer
Pancreas
Phases of clinical research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations